ClinicalTrials.gg
CompletedNCT03443843Updated Dec 20, 2019

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

A Phase 4 interventional study of loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) and Placebo tablet in Rhinitis, Allergic, sponsored by Bayer. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-12-20.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Rhinitis, Allergic with a site in Canada — 3 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · Canada.

Enrollment
17th of 45
82 · median 60
Started
2018
with 3 others
Phase 4
7 of 49
1 open now
Registered
33rd of 49
by date
Lead sponsor
2 of 49
Bayer

Among the 49 studies in Rhinitis, Allergic with a site in Canada, this one is the 17th largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2018, is one of 7 in phase 4, and was the 33rd registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

3 of the 49 studies in Rhinitis, Allergic with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Rhinitis, Allergic with a site in Canada, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.

03

Conditions studied

  • Rhinitis, Allergic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory male and female subjects between 18 to 65 years of age
  • Self-reported seasonal allergic rhinitis to ragweed pollen for at least 2 years prior to screening
  • Documented positive skin prick test response to common ragweed (ambrosia artemisiifolia) pollen at screening or within the previous 12 months conducted at research site (prick with wheal diameter >= 5 mm larger than the diluent response)
  • In order to qualify to continue to treatment phase, at the end of priming phase (which is 3 hours), Total Symptom Score (TSS) has to be ≥ 7, with nasal congestion score alone ≥ 2 and change in peak nasal inspiratory flow (PNIF) has to be ≥ 15% from pre-prime baseline;
  • Subject is willing to stop use of current decongestant and allergy medications at the start of the prior to priming and during the trial
  • At the discretion of the investigators, subjects may be considered with self-reported mild intermittent asthma (Using \<=2 doses of SABA (short-acting beta agonists) per week) or exercise-induced asthma
  • Subject is free of any disease that required a physician´s care and/or would interfere with trial evaluations, procedures or participation
  • Subject is able to repeatedly and reliably perform PNIF measurements and must achieve PNIF value of >=60L/min at screening
  • Subject must be capable of reading English and willing to participate in all aspects of the study

Exclusion criteria

Exclusion Criteria:

  • Any significant medical condition which, in the judgment of the investigator, is a to the use of loratadine, pseudoephedrine and fluticasone propionate, or might interfere with the trial. These may include subjects with injury or surgery to the nose that is not fully healed, fungal infections, conditions (, tuberculosis), severe nosebleeds, narrow-angle glaucoma, chickenpox measles..., severe facial pain or thick nasal discharge, sinusitis, constant whistling sound from the nose, structured abnormality of the nose, uncontrolled thyroid disease (e.g., hyperthyroidism, hypothyroidism), uncontrolled diabetes mellitus, coronary heart disease ischemic heart disease, uncontrolled high blood pressure, symptomatic prostatic hypertrophy, bladder neck obstruction, hepatic insufficiency, renal disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.

    Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) · Drug: Placebo tablet · Drug: Fluticasone Propionate · Drug: Placebo spray

  • Experimental
    Sequence 2

    Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.

    Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) · Drug: Placebo tablet · Drug: Fluticasone Propionate · Drug: Placebo spray

  • Experimental
    Sequence 3

    Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.

    Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) · Drug: Placebo tablet · Drug: Fluticasone Propionate · Drug: Placebo spray

  • Experimental
    Sequence 4

    Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.

    Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) · Drug: Placebo tablet · Drug: Fluticasone Propionate · Drug: Placebo spray

Interventions

  • Drugloratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)

    Drug pages: Loratadine · (+)-pseudoephedrine sulfate

    Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally

  • DrugPlacebo tablet

    Placebo tablet orally

  • Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril

  • DrugPlacebo spray

    Placebo Nasal Spray, 2 sprays per nostril

06

What researchers measure

Primary outcomes

  1. Average percent change in PNIF (Peak Nasal Inspiratory Flow) from 0 to 4 hours after dosing

    Time frame: Up to 4 hours

07

Study locations

1 site
  • Kingston General Hospital
    Kingston, Ontario K7L 2V7, Canada
08

References and documents

Publications

  • Ng CC, Romaikin D, Steacy LM, Stevens DA, Walker TJ, Adams DE, Ellis AK. Comparative nasal airflow with loratadine-pseudoephedrine and fluticasone nasal spray for allergic rhinitis. Ann Allergy Asthma Immunol. 2021 Sep;127(3):342-348.e2. doi: 10.1016/j.anai.2021.05.001. Epub 2021 May 14. PubMed 34000435 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in May 2018, 2 months.

Of 34 phase 4 interventional studies under Rhinitis, Allergic, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 38. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2018
First posted
Feb 23, 2018
StartActual
Feb 21, 2018
Primary completionActual
May 11, 2018
CompletionActual
May 11, 2018
Last update
Dec 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03443843
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Feb 21, 2018
Primary completion
May 11, 2018
Completion
May 11, 2018
Last update
Dec 20, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Loratadine · (+)-pseudoephedrine sulfate · Fluticasone

Start the discussion